Nitric Oxide Technology
R-107 is a patented nitric oxide-releasing compound for treatment of Covid-19 and other viral infections
Nitric oxide is the immune system’s first line of defense against viral infection. When a viral threat is present, white blood cells migrate to the area of infection and release a burst of nitric oxide that crosses into the infected cell to inactivate the virus.
There is an extensive body of research demonstrating the ability of nitric oxide to prevent the replication and transmission of various viruses, such as those that cause COVID-19 infection, as well as viruses that cause influenza and the common cold.
In COVID-19 infections, natural nitric oxide levels may not be sufficient to eradicate the virus. R-107 augments the body’s natural release of nitric oxide to strengthen the body’s ability to eliminate the virus. Unlike vaccine therapy, which may prove ineffective against new mutations, R-107 is engineered to treat all current and future mutant forms of COVID-19.
R-107 is designed to augment the body’s natural release of nitric oxide to significantly hasten and strengthen the body’s ability to combat viruses.
Claritas is developing R-107 as both a therapy for COVID-19 infection, as well as a broad-spectrum antiviral drug for the treatment of, and possible prevention of, other viral infections.
Unlike nitric oxide, which is a gas that must be administered by a trained respiratory therapists using special delivery equipment, R-107 is a liquid that can be easily administered orally in a capsule, or nasally though use of a nasal spray, or by a single intramuscular injection. Due to its ease of administration, R-107 is designed to overcome the challenges inherent in administration of nitric oxide gas, and transform nitric oxide therapy into a potentially best-of-care treatment for COVID-19 infection, and potentially other viral infections as well.